What Edgewise Therapeutics, Inc. does.

At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule engineering to build our proprietary, muscle focused drug discovery platform. Our platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. We have developed and characterized a library of novel sarcomere modulators exhibiting a broad range of pharmacological and pharmacokinetic (PK) properties regulating disease-related muscle biology. Based on the results of our drug discovery platform, we are advancing multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, as well as a number of preclinical programs.

Revenue and profit, by fiscal year.

More on EWTX.

• Edgewise Therapeutics, Inc. summary
• Edgewise Therapeutics, Inc. financial statements
• Edgewise Therapeutics, Inc. key metrics
• Edgewise Therapeutics, Inc. health scores and style box
• Edgewise Therapeutics, Inc. earnings
• Edgewise Therapeutics, Inc. dividends
• Edgewise Therapeutics, Inc. valuation
• Edgewise Therapeutics, Inc. ownership and insiders
• Edgewise Therapeutics, Inc. peers

Figures from Edgewise Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.